Avelumab and Axitinib Combination in Adenoid Cystic Carcinoma

Avelumab and Axitinib Combination in Adenoid Cystic Carcinoma

• March 29, 2023
• Reading time: 1 minute

On March 10, 2023, Dr. Renata Ferrarotto and colleagues from The University of Texas MD Anderson Cancer Center published the efficacy and safety results of a Phase 2 clinical trial evaluating the combination of Avelumab and Axitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) in the Journal of Clinical Oncology.

Study Design: This was an open-label, single-arm Phase 2 clinical trial evaluating the combination of Avelumab (an anti-PD-L1 antibody) and Axitinib (a VEGFR inhibitor) in 40 patients with recurrent or metastatic ACC. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.

Clinical Outcomes: In the evaluable population of 28 patients:

• Objective Response Rate (ORR): 18% (exceeding the primary target).
• 6-Month ORR: 14%.
• Median PFS: 7.3 months.
• 6-Month PFS Rate: 57%.
• Median Overall Survival (OS): 16.6 months.

Safety Profile: The most common adverse events reported by patients included fatigue (62%), hypertension (32%), and diarrhea (32%).

Conclusion: Based on the Phase 2 trial results, Dr. Renata Ferrarotto concluded that the combination of Avelumab and Axitinib demonstrated significant activity in recurrent or metastatic adenoid cystic carcinoma, with an ORR of 18% successfully meeting the study's primary objective.

Source: https://ascopubs.org/doi/abs/10.1200/JCO.22.02221

• Discovering the Key to Aggressive Pancreatic Cancer!
• New Immune Enhancers Boosting Cancer Immunotherapy
• Kyoto University Launches iPS Cell Cancer Therapy!

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4